Citius Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Citius Pharmaceuticals has a total shareholder equity of $85.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $97.4M and $12.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$20.35m |
| Equity | US$85.33m |
| Total liabilities | US$12.07m |
| Total assets | US$97.40m |
Recent financial health updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Recent updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
Dec 25Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK
Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06
Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely
Aug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Jul 05Critical Care Biopharma - Citius Pharmaceuticals
Apr 13Citius: 2022 Is A Year Of Catalysts
Mar 28We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Dec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth
Aug 28Citius: Halt For Superiority On The Horizon
Jun 15We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
May 15Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
Apr 26Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?
Dec 18Financial Position Analysis
Short Term Liabilities: CTXR's short term assets ($28.2M) exceed its short term liabilities ($5.6M).
Long Term Liabilities: CTXR's short term assets ($28.2M) exceed its long term liabilities ($6.5M).
Debt to Equity History and Analysis
Debt Level: CTXR is debt free.
Reducing Debt: CTXR has no debt compared to 5 years ago when its debt to equity ratio was 0.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTXR has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CTXR is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.